Market Research Report
Valrox (Valoctocogene Roxaparvovec)- Emerging Drug Insight and Market Forecast - 2030
|Published by||DelveInsight Business Research LLP||Product code||973287|
|Published||Pre-Order||Content info||60 Pages
Delivery time: 10 business days
|Valrox (Valoctocogene Roxaparvovec)- Emerging Drug Insight and Market Forecast - 2030|
|Published: Pre-Order||Content info: 60 Pages||
"Valrox (Valoctocogene Roxaparvovec)- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Haemophilia A in 7 Major Markets. A detailed picture of the VALROX (VALOCTOCOGENE ROXAPARVOVEC) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Valoctocogene roxaparvovec, is an investigational gene therapy in clinical trials for the treatment of Hemophilia A and has not been determined to be safe or effective. Valoctocogene roxaparvovec is administered as a single infusion. The ongoing clinical trials will determine if the new gene will enable the body to produce factor VIII. Following infusion, clinical trial subjects are being evaluated to determine the safety profile, changes in Factor VIII activity levels, changes in factor replacement usage, changes in reported bleeds requiring factor replacement, and quality of life measures, among other endpoints. The current standard of care for most hemophilia A patients who are severely affected today is a prophylactic regimen of intravenous infusions three times per week. Even with prophylactic regimens, many patients still experience spontaneous bleeding events.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
VALROX (VALOCTOCOGENE ROXAPARVOVEC) Analytical Perspective by DelveInsight
This report provides a detailed market assessment of VALROX (VALOCTOCOGENE ROXAPARVOVEC) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of VALROX (VALOCTOCOGENE ROXAPARVOVEC) covering trial interventions, trial conditions, trial status, start and completion dates.